Answers are grounded in this paper and cite their sources.
Review examines point-of-care antimicrobial resistance diagnostics for Neisseria gonorrhoeae, indicating their promise for resistance-guided therapy.
The increasing rates of antimicrobial resistance (AMR) in Neisseria gonorrhoeae (NG) pose a challenge to the successful future treatment of gonorrhea. Although antimicrobial susceptibility testing (AST) is not routinely performed for NG, detection of antimicrobial susceptibility at the point-of-care (POC) could help guide treatment, including the re-use of previously-recommended treatment. We review the landscape of commercially-available tests and those under development for the rapid determination of AMR in NG. Additionally, we discuss the performance of new and novel nucleic acid-based phenotypic approaches for rapid characterization of AMR, which could potentially be implemented at the POC for resistance-guided therapy. Lastly, issues regarding the implementation of POC tests for resistance testing are discussed.
No takes yet. Share an insight, caveat, or question.
Melendez et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: